News & Press Releases

Mintz advised the underwriters in connection with a $50 million follow-on offering by Eledon Pharmaceuticals.

Mintz advised Diamond Antenna and Microwave Corporation, a developer of advanced radio frequency and electro-mechanical solutions and a portfolio company of Artemis Capital Partners, on its acquisition of Antenna Associates, a developer of antenna systems for military and commercial applications. This transaction follows Mintz’s representation of Artemis in its 2024 acquisition of Diamond Antenna and Microwave Corporation.

Mintz advised the underwriter in connection with a $75 million registered direct offering by Precision BioSciences, Inc. 

Mintz advised the underwriters in connection with Benitec Biopharma’s follow-on public offering of 5,930,000 shares of common stock at a public offering price of $13.50 per share, and the placement agents in the concurrent registered direct offering of 1,481,481 shares of common stock at an offering price of $13.50 per share. The aggregate gross proceeds to Benitec Biopharma from these offerings were approximately $100 million before deducting underwriting discounts and commissions, placement agent fees, and other offering expenses. In addition, Benitec Biopharma granted the underwriters a 30-day option to purchase up to an additional 889,500 shares of its common stock at the public offering price.

Mintz advised the underwriter in connection with a $75 million underwritten offering by MoonLake Immunotherapeutics of 7,142,857 Class A ordinary shares at an offering price of $10.50 per share. The aggregate gross proceeds to MoonLake Immunotherapeutics from this offering were approximately $75 million before deducting underwriting discounts and commissions and other offering expenses.

Of Counsel Michelle Capezza shared insights with Fiduciary News about the complexities of ERISA fiduciary roles and the distinction between 3(21) advisors and 3(38) investment managers. A 3(21) co-fiduciary advisor provides non-discretionary advice in partnership with the plan committee, who retains the responsibility to make investment decisions, while the 3(38) model delegates true discretion to a 3(38) manager, limiting the committee’s responsibility to the prudent selection and oversight of that manager.